NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
HeartBeam Inc. Q3 2025 Conference Call and Cardiac Technology FAQ
TL;DR
HeartBeam's upcoming Q3 results and regulatory updates could reveal competitive advantages in portable cardiac monitoring technology for investors seeking growth opportunities.
HeartBeam's 3D ECG technology collects signals from three directions and synthesizes them into 12-lead ECGs using portable devices with over 20 issued patents.
HeartBeam's portable ECG technology enables remote cardiac monitoring, improving access to heart health management and potentially saving lives outside medical facilities.
HeartBeam is creating the first cable-free device that captures 3D ECG signals, transforming how cardiac conditions are detected and monitored anywhere.
Found this article helpful?
Share it with your network and spread the knowledge!
The conference call will discuss HeartBeam's third quarter 2025 financial results for the period ended September 30, 2025, and provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones.
The conference call is scheduled for Thursday, November 13, 2025, at 4:30 p.m. Eastern Time, and will be accessible via the details provided in the press release that will be issued prior to the call.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, enabling portable cardiac monitoring outside medical facilities.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software is currently under FDA review.
The technology allows physicians to identify cardiac health trends and acute conditions from portable devices used wherever the patient is, enabling them to direct patients to appropriate care outside of medical facilities.
HeartBeam holds over 20 issued patents related to technology enablement, providing strong intellectual property protection for their innovative cardiac monitoring platform.
The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
The full press release can be viewed at https://ibn.fm/5mXsb, which will be issued prior to the conference call with complete details.
HeartBeam is dedicated to transforming the detection and monitoring of critical cardiac conditions through personalized insights and portable ECG technology that delivers actionable heart intelligence.
Curated from InvestorBrandNetwork (IBN)
